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Editorial
Advances in the basic science of cancer, genetic studies, mo-
lecular biology and different modalities of therapy including
chemotherapy, radiotherapy, surgery and supportive care
have occurred in the last few decades. Improvement in his-
tological, immunological and cytogenetic techniques has
made the diagnosis and classification more accurate. The
development of multiple-agent chemotherapy, targeted and
pharmacogenetic therapies as well as hematopoietic stem cell
transplantation hold great promise for the future. Molecular
HLA-typing techniques and the international donor
registries have solved the problem of finding appropriate
donors for transplantation. In addition, progress in palliative
care has provided a degree of comfort for patients under-
going chemotherapy, radiotherapy and surgery.
Recently targeted cancer therapy has made a good impact in
treatment of childhood chronic myeloid leukemia (CML)
and Philadelphia positive acute lymphoblastic leukemia (Ph+
ALL). The Ph+ is due to reciprocal translocation of the long
arms of chromosomes 9 and 22, t (9:22) (q34; q11), which
results in a fusion gene BCR-ABL, encoding a constitutively
active tyrosine kinase. The BCR-ABL tyrosine kinase inhibi-
tor (TKI), imatinib, is now used in treatment of Pediatric
CML as well as Ph+ALL. It selectively inhibits the tyrosine
kinase domain in the Abelson proto-oncogene (ABL) and
targets the tyrosine kinase C-kit and platelet – derived
growth factor receptor (PDGF-R) which causes the muta-
tions found in both myeloid and lymphoid malignancies.1, 2
As a result, phosphorylation of ABL-tyrosine kinase sub-
strates fails to occur and prevent activation of leukemogenic
signal transduction. It was approved in 2001 for treatment of
CML and in 2013 for treatment of Pediatric Ph+ALL.
A report from the children's Oncology group has recorded
success in treatment of de-novo chronic phase CML in chil-
dren in 80% of cases.3 CML comprises 2-3% of all childhood
leukemia. Response to treatment with imatinib appears to be
better in children than in adults.4, 5, 6 Recently, the use of
imatinib alone in treating CML in children is considered
when no HLA-identical donor for stem cell transplantation
is available.
The high-risk Ph+ALL represents 3-5% of childhood ALL.7
The use of chemotherapy alone in its treatment results in less
than 30% event-free survival rates.8 Children Oncology
Group (COG) reported improved outcomes of children with
Ph+ALL treated with imatinib and chemotherapy.9 Its role in
pre-and post-hematopoietic stem cell transplantation is still
under study and evaluation.10 In conclusion, the targeted
imatinib therapy dramatically improved the outcomes of
children with CML and Ph+ALL.
Currently, several novel targeted therapeutic strategies are
being investigated. They include Troxacitabine (a nucleoside
analogue), Decitabine (a hypomethylating agent), R15777
SCH66336 (farnesyl transferase inhibitor), Homoharringtone
(a plant alkaloid), PS-341 (a proteosome inhibitor), PR1 vac-
cine, polyethylene glycol IFN-α preparations, and inhibitor
of heat shock protein 90 (a molecular chaperone required for
stability of signal proteins). Success of these novel drugs will
add a major advance in combating malignancy.
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